Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CYTOKINETICS INCCYTK · Entity 3528 | EVP, Chief Legal Officer | August 30, 2024 | September 03, 2024 |
| GILEAD SCIENCES, INC.GILD · Entity 405 | EVP,Corp Affairs & Gen Counsel | June 10, 2022 | June 14, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CYTOKINETICS INC
Report date August 30, 2024 · Filed September 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 33,140 |
Reported balance
After 2024-08-30 transaction · row 1
1 source rowRow 1 · 2024-08-30 · Grant · Acquired 33,140 · Balance 33,140 F1: Inducement grant comprised of restricted stock units ("RSUs") that are converted into shares of common stock on a 1:1 basis upon time based vesting. 40% of the RSUs vest on the 1-year anniversary of the grant date, an additional 40% of the RSUs vest on the 2-year anniversary of the grant date, and the remaining 20% of the RSUs vest on the 3-year anniversary of the grant date, in each case subject to the grantee's continued employment with the company. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $57.08 · Expires 2034-08-30 | Direct | 51,039 |
Reported balance
After 2024-08-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-08-30 · Grant · Acquired 51,039 · Balance 51,039 F2: Inducement grant comprised of stock options to purchase shares of common stock subject to time lapse vesting. 25% of the stock options vest on the 1-year anniversary of the grant date and the remaining 75% of the stock options vest in equal monthly installments over the subsequent 3 years to the 1-year anniversary of the grant date, with each installment vesting subject to the grantee's continued employment with the company. |
Filing footnotes · ownership attribution and instrument terms
F1: Inducement grant comprised of restricted stock units ("RSUs") that are converted into shares of common stock on a 1:1 basis upon time based vesting. 40% of the RSUs vest on the 1-year anniversary of the grant date, an additional 40% of the RSUs vest on the 2-year anniversary of the grant date, and the remaining 20% of the RSUs vest on the 3-year anniversary of the grant date, in each case subject to the grantee's continued employment with the company.
F2: Inducement grant comprised of stock options to purchase shares of common stock subject to time lapse vesting. 25% of the stock options vest on the 1-year anniversary of the grant date and the remaining 75% of the stock options vest in equal monthly installments over the subsequent 3 years to the 1-year anniversary of the grant date, with each installment vesting subject to the grantee's continued employment with the company.
GILEAD SCIENCES, INC.
Report date June 10, 2022 · Filed June 14, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 33,426 |
Ending reported balance
After 2022-06-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-06-10 · Exercise / conversion · Acquired 782 · Balance 33,706 F1: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Row 2 · 2022-06-10 · Tax withholding · Disposed 280 · Balance 33,426 |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 16,519 |
Reported balance
After 2022-06-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-06-10 · Exercise / conversion · Disposed 782 · Balance 16,519 F1: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
F2: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 10, 2020 Filed Feb 12, 2020 23:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,950 | $69.32 | $204,494.00 |
DisclosureSEC source: 0001127602-20-005129 · form4.xml · nonDerivative · entry 2 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,690 Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 23:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,950 | $24.30 | $71,670.25 |
DisclosureSEC source: 0001127602-20-005129 · form4.xml · nonDerivative · entry 1 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,640 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| February 07, 2020 Filed Feb 11, 2020 00:00 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,426 | $70.00 | $99,820.00 |
DisclosureSEC source: 0001127602-20-004716 · form4.xml · nonDerivative · entry 5 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,690 Read SEC document |
| February 06, 2020 Filed Feb 11, 2020 00:00 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 2,728 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-004716 · form4.xml · derivative · entry 7 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,182 Underlying: Common Stock · 2,728 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. F3 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| February 06, 2020 Filed Feb 11, 2020 00:00 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $40.56 | $0.00 |
DisclosureSEC source: 0001127602-20-004716 · form4.xml · derivative · entry 6 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,560 Underlying: Common Stock · 5,000 shares Expires 2023-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| February 06, 2020 Filed Feb 11, 2020 00:00 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 1,302 | $68.21 | $88,809.42 |
DisclosureSEC source: 0001127602-20-004716 · form4.xml · nonDerivative · entry 4 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,116 Read SEC document |
| February 06, 2020 Filed Feb 11, 2020 00:00 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,728 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-004716 · form4.xml · nonDerivative · entry 3 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,418 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| February 06, 2020 Filed Feb 11, 2020 00:00 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,000 | $68.18 | $340,900.50 |
DisclosureSEC source: 0001127602-20-004716 · form4.xml · nonDerivative · entry 2 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,690 Read SEC document |
| February 06, 2020 Filed Feb 11, 2020 00:00 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 5,000 | $40.56 | $202,800.00 |
DisclosureSEC source: 0001127602-20-004716 · form4.xml · nonDerivative · entry 1 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,690 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 23:23 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 4,587 | $64.30 | $294,944.10 |
DisclosureSEC source: 0001127602-20-002965 · form4.xml · nonDerivative · entry 3 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,690 Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 23:23 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 4,126 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-002965 · form4.xml · nonDerivative · entry 2 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,277 F2 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 2, 2017. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 23:23 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 8,087 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-002965 · form4.xml · nonDerivative · entry 1 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,151 F1 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on February 1, 2018, and February 6, 2019. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until the requisite continuing service requirements are also met. Read SEC document |
| January 03, 2020 Filed Jan 7, 2020 00:01 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 2,950 | $0.00 Strike: $24.30 | $0.00 |
DisclosureSEC source: 0001127602-20-001254 · form4.xml · derivative · entry 3 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,550 Underlying: Common Stock · 2,950 shares Expires 2022-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The shares subject to the option have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| January 03, 2020 Filed Jan 7, 2020 00:01 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,950 | $64.63 | $190,658.50 |
DisclosureSEC source: 0001127602-20-001254 · form4.xml · nonDerivative · entry 2 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,064 Read SEC document |
| January 03, 2020 Filed Jan 7, 2020 00:01 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,950 | $24.30 | $71,670.25 |
DisclosureSEC source: 0001127602-20-001254 · form4.xml · nonDerivative · entry 1 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,014 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 00:11 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 5,900 | $0.00 Strike: $24.30 | $0.00 |
DisclosureSEC source: 0001127602-19-034297 · form4.xml · derivative · entry 3 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,500 Underlying: Common Stock · 5,900 shares Expires 2022-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The shares subject to the option have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 00:11 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,900 | $65.77 | $388,043.00 |
DisclosureSEC source: 0001127602-19-034297 · form4.xml · nonDerivative · entry 2 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,064 Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 00:11 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 5,900 | $24.30 | $143,340.50 |
DisclosureSEC source: 0001127602-19-034297 · form4.xml · nonDerivative · entry 1 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,964 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 19:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $40.56 | $0.00 |
DisclosureSEC source: 0001127602-19-033740 · form4.xml · derivative · entry 3 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,560 Underlying: Common Stock · 15,000 shares Expires 2023-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares subject to the option have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 19:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 15,000 | $66.85 | $1,002,808.50 |
DisclosureSEC source: 0001127602-19-033740 · form4.xml · nonDerivative · entry 2 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,064 F1 · price: Sale prices reported for the transactions reported here range from $66.85 to $66.88. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 19:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 15,000 | $40.56 | $608,400.00 |
DisclosureSEC source: 0001127602-19-033740 · form4.xml · nonDerivative · entry 1 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,064 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 19, 2019 Filed Nov 20, 2019 23:11 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $24.30 | $0.00 |
DisclosureSEC source: 0001127602-19-033438 · form4.xml · derivative · entry 7 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,400 Underlying: Common Stock · 10,000 shares Expires 2022-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares subject to the option have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| November 19, 2019 Filed Nov 20, 2019 23:11 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 10,000 | $64.91 | $649,062.00 |
DisclosureSEC source: 0001127602-19-033438 · form4.xml · nonDerivative · entry 5 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,064 F3 · price: Sale prices reported for the transactions reported here range from $64.90 to $64.93. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| November 19, 2019 Filed Nov 20, 2019 23:11 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 10,000 | $24.30 | $242,950.00 |
DisclosureSEC source: 0001127602-19-033438 · form4.xml · nonDerivative · entry 4 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,064 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 18, 2019 Filed Nov 20, 2019 23:11 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $24.30 | $0.00 |
DisclosureSEC source: 0001127602-19-033438 · form4.xml · derivative · entry 6 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,400 Underlying: Common Stock · 10,000 shares Expires 2022-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares subject to the option have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| November 18, 2019 Filed Nov 20, 2019 23:11 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 10,000 | $63.85 | $638,500.00 |
DisclosureSEC source: 0001127602-19-033438 · form4.xml · nonDerivative · entry 3 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,064 Read SEC document |
| November 18, 2019 Filed Nov 20, 2019 23:11 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 10,000 | $24.30 | $242,950.00 |
DisclosureSEC source: 0001127602-19-033438 · form4.xml · nonDerivative · entry 2 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,064 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 14, 2019 Filed Nov 20, 2019 23:11 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GiftCommon Stock | 762 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-033438 · form4.xml · nonDerivative · entry 1 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,064 F1 · shares: Shares gifted to charitable trust Read SEC document |
| November 05, 2019 Filed Nov 8, 2019 01:04 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,095 | $66.06 | $138,403.66 |
DisclosureSEC source: 0001127602-19-032265 · form4.xml · nonDerivative · entry 1 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,826 F1 · price: Sale prices reported for the transactions reported here range from $66.06 to $66.07. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| November 01, 2019 Filed Nov 6, 2019 01:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 2,400 | $0.00 Strike: $16.89 | $0.00 |
DisclosureSEC source: 0001127602-19-031974 · form4.xml · derivative · entry 3 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,400 shares Expires 2020-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to the option have a five-year vesting schedule. 20% vest on the first anniversary of the date of the grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| November 01, 2019 Filed Nov 6, 2019 01:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 4,000 | $64.52 | $258,098.80 |
DisclosureSEC source: 0001127602-19-031974 · form4.xml · nonDerivative · entry 2 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,921 F2 · price: Sale prices reported for the transactions reported here range from $64.5201 to $64.53. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| November 01, 2019 Filed Nov 6, 2019 01:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,400 | $16.89 | $40,536.00 |
DisclosureSEC source: 0001127602-19-031974 · form4.xml · nonDerivative · entry 1 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,921 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 28, 2019 Filed Oct 31, 2019 00:35 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,677 | $63.31 | $359,412.01 |
DisclosureSEC source: 0001127602-19-031294 · form4.xml · nonDerivative · entry 1 Pletcher Brett A · CIK 0001739307 · EVP, Gen Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,521 F1 · price: Sale prices reported for the transactions reported here range from $63.31 to $63.3102. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| August 19, 2019 Filed Aug 20, 2019 19:13 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 608 | $64.35 | $39,123.46 |
DisclosureSEC source: 0001127602-19-027052 · form4.xml · nonDerivative · entry 1 Pletcher Brett A · CIK 0001739307 · EVP, Gen Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,198 F1 · price: Sale prices reported for the transactions reported here range from $64.3433 to $64.35. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| August 10, 2019 Filed Aug 13, 2019 22:48 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 1,070 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-026569 · form4.xml · derivative · entry 3 Pletcher Brett A · CIK 0001739307 · EVP, Gen Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,910 Underlying: Common Stock · 1,070 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| August 10, 2019 Filed Aug 13, 2019 22:48 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 462 | $65.24 | $30,140.88 |
DisclosureSEC source: 0001127602-19-026569 · form4.xml · nonDerivative · entry 2 Pletcher Brett A · CIK 0001739307 · EVP, Gen Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,806 Read SEC document |
| August 10, 2019 Filed Aug 13, 2019 22:48 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 1,070 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-026569 · form4.xml · nonDerivative · entry 1 Pletcher Brett A · CIK 0001739307 · EVP, Gen Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,268 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| July 23, 2019 Filed Jul 25, 2019 22:37 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 7,200 | $0.00 Strike: $24.91 | $0.00 |
DisclosureSEC source: 0001127602-19-025217 · form4.xml · derivative · entry 3 Pletcher Brett A · CIK 0001739307 · EVP, Gen Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,200 shares Expires 2019-07-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The shares subject to the option have a five-year vesting schedule. 20% vest on the first anniversary of the date of the grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| July 23, 2019 Filed Jul 25, 2019 22:37 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 7,200 | $65.07 | $468,504.00 |
DisclosureSEC source: 0001127602-19-025217 · form4.xml · nonDerivative · entry 2 Pletcher Brett A · CIK 0001739307 · EVP, Gen Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,198 Read SEC document |
| July 23, 2019 Filed Jul 25, 2019 22:37 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 7,200 | $24.91 | $179,316.00 |
DisclosureSEC source: 0001127602-19-025217 · form4.xml · nonDerivative · entry 1 Pletcher Brett A · CIK 0001739307 · EVP, Gen Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,398 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| June 18, 2019 Filed Jun 20, 2019 20:52 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,816 | $68.75 | $399,850.00 |
DisclosureSEC source: 0001127602-19-022379 · form4.xml · nonDerivative · entry 1 Pletcher Brett A · CIK 0001739307 · EVP, Gen Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,198 F1 · kind: The sale transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| February 15, 2019 Filed Mar 14, 2019 20:31 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 330 | $57.45 | $18,959.00 |
DisclosureSEC source: 0001127602-19-011363 · form4.xml · nonDerivative · entry 1 Pletcher Brett A · CIK 0001739307 · EVP, Gen Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,014 F1 · shares: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Gilead Sciences, Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of August 16, 2018 through February, 15 2019. This transaction is exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on February 15, 2019. Read SEC document |
| February 06, 2019 Filed Feb 9, 2019 00:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 10,910 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-004920 · form4.xml · derivative · entry 5 Pletcher Brett A · CIK 0001739307 · EVP, Gen Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,980 Underlying: Common Stock · 10,910 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. F3 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| February 06, 2019 Filed Feb 9, 2019 00:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 50,480 | $0.00 Strike: $68.75 | $0.00 |
DisclosureSEC source: 0001127602-19-004920 · form4.xml · derivative · entry 4 Pletcher Brett A · CIK 0001739307 · EVP, Gen Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,480 Underlying: Common Stock · 50,480 shares Expires 2029-02-06 F1 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| February 06, 2019 Filed Feb 9, 2019 00:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 3,871 | $68.75 | $266,131.25 |
DisclosureSEC source: 0001127602-19-004920 · form4.xml · nonDerivative · entry 3 Pletcher Brett A · CIK 0001739307 · EVP, Gen Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,684 Read SEC document |
| February 06, 2019 Filed Feb 9, 2019 00:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 6,463 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-004920 · form4.xml · nonDerivative · entry 2 Pletcher Brett A · CIK 0001739307 · EVP, Gen Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,555 F5 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 1, 2016. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. Read SEC document |
| February 06, 2019 Filed Feb 9, 2019 00:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 9,386 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-004920 · form4.xml · nonDerivative · entry 1 Pletcher Brett A · CIK 0001739307 · EVP, Gen Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,092 F4 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on February 1, 2016, and February 16, 2017. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until the requisite continuing service requirements are also met. Read SEC document |
| August 15, 2018 Filed Sep 19, 2018 18:29 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 94 | $63.61 | $5,979.72 |
DisclosureSEC source: 0001127602-18-028011 · form4.xml · nonDerivative · entry 1 Pletcher Brett A · CIK 0001739307 · EVP, Gen Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,706 F1 · shares: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Gilead Sciences, Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of February 16, 2018 through August, 15 2018. This transaction is exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on August 15, 2018. Read SEC document |
| August 10, 2018 Filed Aug 14, 2018 18:05 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 1,070 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-025255 · form4.xml · derivative · entry 3 Pletcher Brett A · CIK 0001739307 · EVP, Gen Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,070 Underlying: Common Stock · 1,070 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| August 10, 2018 Filed Aug 14, 2018 18:05 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 489 | $76.73 | $37,520.97 |
DisclosureSEC source: 0001127602-18-025255 · form4.xml · nonDerivative · entry 2 Pletcher Brett A · CIK 0001739307 · EVP, Gen Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,612 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.